Price and medical insurance reimbursement reference of sparsentan in China

Sparsentan (Sparsentan) is a new type of renal protection drug, mainly used to treat primary nephrotic syndrome and certain hyperalbuminuria diseases. The drug simultaneously inhibits angiotensin II receptors and endothelin receptors through a dual mechanism of action, thereby reducing proteinuria and delaying the decline of renal function. As of now, sparsentan has not been officially launched in China, and patients can only obtain the drug through formal overseas channels.

In overseas markets, the original version of Sparsentan is more expensive, with a box selling for about 40,000 to 50,000 yuan. Since the drug is an imported original drug, its manufacturing cost, R&D investment and international pricing strategy jointly determine the high market price. For patients who require long-term treatment, the financial burden of original drugs is relatively heavy, especially when they are not included in the medical insurance system, and the out-of-pocket proportion is entirely borne by the patient.

To alleviate the high cost, some patients can choose a generic version produced in Laos. Each box of generic drugs in Laos sells for about 7,000 to 8,000 yuan, which is several times cheaper than the original drugs. The ingredients of the drugs are basically the same as the original drugs, and the clinical effects can be used as an alternative. However, due to exchange rate fluctuations and differences in overseas transportation costs, the actual drug purchase price may vary, so patients should confirm the specific cost with the channel before purchasing.

Currently, Spasentan has not been included in China’s medical insurance catalog, so domestic patients cannot reduce their out-of-pocket pressure through medical insurance. If it is included in medical insurance reimbursement in the future, the financial burden on patients will be significantly reduced, and the actual monthly expenditure may be reduced several times. It is recommended that patients choose formal channels when purchasing overseas and evaluate the course of treatment and dosage under the guidance of a doctor to ensure safe medication and economic feasibility.

Reference materials:https://www.drugs.com/